Report cover image

RNA Vaccines Industry Research Report 2025

Publisher APO Research, Inc.
Published Oct 20, 2025
Length 129 Pages
SKU # APRC20543403

Description

Summary

According to APO Research, the global RNA Vaccines market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.

North American market for RNA Vaccines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for RNA Vaccines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for RNA Vaccines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of RNA Vaccines include Translate Bio, Tiba Biotechnology, Sangamo Therapeutics, Moderna Therapeutics, In-Cell-Art, Ethris, eTheRNA, CureVac and BioNTech, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope
This report aims to provide a comprehensive presentation of the global market for RNA Vaccines, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding RNA Vaccines.

The report will help the RNA Vaccines manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
The RNA Vaccines market size, estimations, and forecasts are provided in terms of sales volume (k units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global RNA Vaccines market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.
RNA Vaccines Segment by Company
Translate Bio Tiba Biotechnology Sangamo Therapeutics Moderna Therapeutics In-Cell-Art Ethris eTheRNA CureVac BioNTech Argos TherapeuticsRNA Vaccines Segment by Type
Individualized Cancer Treatment MRNA Vaccine Infection Prevention MRNA Vaccine Infectious Disease Treatment MRNA VaccineRNA Vaccines Segment by Application
Infectious Disease Cancer OtherRNA Vaccines Segment by Region
North America United States Canada Europe Germany France U.K. Italy Netherlands Asia-Pacific China Japan South Korea India Australia China Taiwan Southeast Asia South America Mexico Brazil Argentina Middle East & Africa Turkey Saudi Arabia UAE

Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global RNA Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of RNA Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of RNA Vaccines.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of RNA Vaccines manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of RNA Vaccines by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of RNA Vaccines in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.

Table of Contents

129 Pages
1 Preface
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 Market Overview
2.1 Product Definition
2.2 Global Market Growth Prospects
2.2.1 Global RNA Vaccines Market Size (2020-2031)
2.2.2 Global RNA Vaccines Sales (2020-2031)
2.2.3 Global RNA Vaccines Market Average Price (2020-2031)
2.3 RNA Vaccines by Type
2.3.1 Market Value Comparison by Type (2020 VS 2024 VS 2031) & (US$ Million)
2.3.2 Individualized Cancer Treatment MRNA Vaccine
2.3.3 Infection Prevention MRNA Vaccine
2.3.4 Infectious Disease Treatment MRNA Vaccine
2.4 RNA Vaccines by Application
2.4.1 Market Value Comparison by Application (2020 VS 2024 VS 2031)
2.4.2 Infectious Disease
2.4.3 Cancer
2.4.4 Other
3 Market Competitive Landscape by Manufacturers
3.1 Global RNA Vaccines Market Competitive Situation by Manufacturers (2020 Versus 2024)
3.2 Global RNA Vaccines Sales (k units) of Manufacturers (2020-2025)
3.3 Global RNA Vaccines Revenue of Manufacturers (2020-2025)
3.4 Global RNA Vaccines Average Price by Manufacturers (2020-2025)
3.5 Global RNA Vaccines Industry Ranking, 2023 VS 2024 VS 2025
3.6 Global Manufacturers of RNA Vaccines, Manufacturing Sites & Headquarters
3.7 Global Manufacturers of RNA Vaccines, Product Type & Application
3.8 Global Manufacturers of RNA Vaccines, Established Date
3.9 Global RNA Vaccines Market CR5 and HHI
3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
4.1 Translate Bio
4.1.1 Translate Bio Company Information
4.1.2 Translate Bio Business Overview
4.1.3 Translate Bio RNA Vaccines Sales, Revenue and Gross Margin (2020-2025)
4.1.4 Translate Bio RNA Vaccines Product Portfolio
4.1.5 Translate Bio Recent Developments
4.2 Tiba Biotechnology
4.2.1 Tiba Biotechnology Company Information
4.2.2 Tiba Biotechnology Business Overview
4.2.3 Tiba Biotechnology RNA Vaccines Sales, Revenue and Gross Margin (2020-2025)
4.2.4 Tiba Biotechnology RNA Vaccines Product Portfolio
4.2.5 Tiba Biotechnology Recent Developments
4.3 Sangamo Therapeutics
4.3.1 Sangamo Therapeutics Company Information
4.3.2 Sangamo Therapeutics Business Overview
4.3.3 Sangamo Therapeutics RNA Vaccines Sales, Revenue and Gross Margin (2020-2025)
4.3.4 Sangamo Therapeutics RNA Vaccines Product Portfolio
4.3.5 Sangamo Therapeutics Recent Developments
4.4 Moderna Therapeutics
4.4.1 Moderna Therapeutics Company Information
4.4.2 Moderna Therapeutics Business Overview
4.4.3 Moderna Therapeutics RNA Vaccines Sales, Revenue and Gross Margin (2020-2025)
4.4.4 Moderna Therapeutics RNA Vaccines Product Portfolio
4.4.5 Moderna Therapeutics Recent Developments
4.5 In-Cell-Art
4.5.1 In-Cell-Art Company Information
4.5.2 In-Cell-Art Business Overview
4.5.3 In-Cell-Art RNA Vaccines Sales, Revenue and Gross Margin (2020-2025)
4.5.4 In-Cell-Art RNA Vaccines Product Portfolio
4.5.5 In-Cell-Art Recent Developments
4.6 Ethris
4.6.1 Ethris Company Information
4.6.2 Ethris Business Overview
4.6.3 Ethris RNA Vaccines Sales, Revenue and Gross Margin (2020-2025)
4.6.4 Ethris RNA Vaccines Product Portfolio
4.6.5 Ethris Recent Developments
4.7 eTheRNA
4.7.1 eTheRNA Company Information
4.7.2 eTheRNA Business Overview
4.7.3 eTheRNA RNA Vaccines Sales, Revenue and Gross Margin (2020-2025)
4.7.4 eTheRNA RNA Vaccines Product Portfolio
4.7.5 eTheRNA Recent Developments
4.8 CureVac
4.8.1 CureVac Company Information
4.8.2 CureVac Business Overview
4.8.3 CureVac RNA Vaccines Sales, Revenue and Gross Margin (2020-2025)
4.8.4 CureVac RNA Vaccines Product Portfolio
4.8.5 CureVac Recent Developments
4.9 BioNTech
4.9.1 BioNTech Company Information
4.9.2 BioNTech Business Overview
4.9.3 BioNTech RNA Vaccines Sales, Revenue and Gross Margin (2020-2025)
4.9.4 BioNTech RNA Vaccines Product Portfolio
4.9.5 BioNTech Recent Developments
4.10 Argos Therapeutics
4.10.1 Argos Therapeutics Company Information
4.10.2 Argos Therapeutics Business Overview
4.10.3 Argos Therapeutics RNA Vaccines Sales, Revenue and Gross Margin (2020-2025)
4.10.4 Argos Therapeutics RNA Vaccines Product Portfolio
4.10.5 Argos Therapeutics Recent Developments
5 Global RNA Vaccines Market Scenario by Region
5.1 Global RNA Vaccines Market Size by Region: 2020 VS 2024 VS 2031
5.2 Global RNA Vaccines Sales by Region: 2020-2031
5.2.1 Global RNA Vaccines Sales by Region: 2020-2025
5.2.2 Global RNA Vaccines Sales by Region: 2026-2031
5.3 Global RNA Vaccines Revenue by Region: 2020-2031
5.3.1 Global RNA Vaccines Revenue by Region: 2020-2025
5.3.2 Global RNA Vaccines Revenue by Region: 2026-2031
5.4 North America RNA Vaccines Market Facts & Figures by Country
5.4.1 North America RNA Vaccines Market Size by Country: 2020 VS 2024 VS 2031
5.4.2 North America RNA Vaccines Sales by Country (2020-2031)
5.4.3 North America RNA Vaccines Revenue by Country (2020-2031)
5.4.4 United States
5.4.5 Canada
5.5 Europe RNA Vaccines Market Facts & Figures by Country
5.5.1 Europe RNA Vaccines Market Size by Country: 2020 VS 2024 VS 2031
5.5.2 Europe RNA Vaccines Sales by Country (2020-2031)
5.5.3 Europe RNA Vaccines Revenue by Country (2020-2031)
5.5.4 Germany
5.5.5 France
5.5.6 U.K.
5.5.7 Italy
5.5.8 Netherlands
5.6 Asia Pacific RNA Vaccines Market Facts & Figures by Country
5.6.1 Asia Pacific RNA Vaccines Market Size by Country: 2020 VS 2024 VS 2031
5.6.2 Asia Pacific RNA Vaccines Sales by Country (2020-2031)
5.6.3 Asia Pacific RNA Vaccines Revenue by Country (2020-2031)
5.6.4 China
5.6.5 Japan
5.6.6 South Korea
5.6.7 India
5.6.8 Australia
5.6.9 China Taiwan
5.6.10 Southeast Asia
5.7 South America RNA Vaccines Market Facts & Figures by Country
5.7.1 South America RNA Vaccines Market Size by Country: 2020 VS 2024 VS 2031
5.7.2 South America RNA Vaccines Sales by Country (2020-2031)
5.7.3 South America RNA Vaccines Revenue by Country (2020-2031)
5.7.4 Mexico
5.7.5 Brazil
5.7.6 Argentina
5.8 Middle East and Africa RNA Vaccines Market Facts & Figures by Country
5.8.1 Middle East and Africa RNA Vaccines Market Size by Country: 2020 VS 2024 VS 2031
5.8.2 Middle East and Africa RNA Vaccines Sales by Country (2020-2031)
5.8.3 Middle East and Africa RNA Vaccines Revenue by Country (2020-2031)
5.8.4 Turkey
5.8.5 Saudi Arabia
5.8.6 UAE
6 Segment by Type
6.1 Global RNA Vaccines Sales by Type (2020-2031)
6.1.1 Global RNA Vaccines Sales by Type (2020-2031) & (k units)
6.1.2 Global RNA Vaccines Sales Market Share by Type (2020-2031)
6.2 Global RNA Vaccines Revenue by Type (2020-2031)
6.2.1 Global RNA Vaccines Sales by Type (2020-2031) & (US$ Million)
6.2.2 Global RNA Vaccines Revenue Market Share by Type (2020-2031)
6.3 Global RNA Vaccines Price by Type (2020-2031)
7 Segment by Application
7.1 Global RNA Vaccines Sales by Application (2020-2031)
7.1.1 Global RNA Vaccines Sales by Application (2020-2031) & (k units)
7.1.2 Global RNA Vaccines Sales Market Share by Application (2020-2031)
7.2 Global RNA Vaccines Revenue by Application (2020-2031)
7.2.1 Global RNA Vaccines Sales by Application (2020-2031) & (US$ Million)
7.2.2 Global RNA Vaccines Revenue Market Share by Application (2020-2031)
7.3 Global RNA Vaccines Price by Application (2020-2031)
8 Value Chain and Sales Channels Analysis of the Market
8.1 RNA Vaccines Value Chain Analysis
8.1.1 RNA Vaccines Key Raw Materials
8.1.2 Raw Materials Key Suppliers
8.1.3 RNA Vaccines Production Mode & Process
8.2 RNA Vaccines Sales Channels Analysis
8.2.1 Direct Comparison with Distribution Share
8.2.2 RNA Vaccines Distributors
8.2.3 RNA Vaccines Customers
9 Global RNA Vaccines Analyzing Market Dynamics
9.1 RNA Vaccines Industry Trends
9.2 RNA Vaccines Industry Drivers
9.3 RNA Vaccines Industry Opportunities and Challenges
9.4 RNA Vaccines Industry Restraints
10 Report Conclusion
11 Disclaimer
List of Tables
Table 1. Secondary Sources
Table 2. Primary Sources
Table 3. Market Value Comparison by Type (2020 VS 2024 VS 2031) & (US$ Million)
Table 4. Market Value Comparison by Application (2020 VS 2024 VS 2031) & (US$ Million)
Table 5. Global RNA Vaccines Volume and Revenue Market Size and CAGR of Manufacturers (2020 Versus 2024)
Table 6. Global RNA Vaccines Sales (k units) of Manufacturers (2020-2025)
Table 7. Global RNA Vaccines Sales Market Share by Manufacturers (2020-2025)
Table 8. Global RNA Vaccines Revenue of Manufacturers (2020-2025)
Table 9. Global RNA Vaccines Revenue Share by Manufacturers (2020-2025)
Table 10. Global Market RNA Vaccines Average Price (US$/unit) of Manufacturers (2020-2025)
Table 11. Global RNA Vaccines Industry Ranking, 2023 VS 2024 VS 2025
Table 12. Global Manufacturers of RNA Vaccines, Manufacturing Sites & Headquarters
Table 13. Global Manufacturers of RNA Vaccines, Product Type & Application
Table 14. Global RNA Vaccines Manufacturers Established Date
Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 16. Global RNA Vaccines by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2024)
Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans)
Table 18. Translate Bio Company Information
Table 19. Translate Bio Business Overview
Table 20. Translate Bio RNA Vaccines Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
Table 21. Translate Bio RNA Vaccines Product Portfolio
Table 22. Translate Bio Recent Developments
Table 23. Tiba Biotechnology Company Information
Table 24. Tiba Biotechnology Business Overview
Table 25. Tiba Biotechnology RNA Vaccines Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
Table 26. Tiba Biotechnology RNA Vaccines Product Portfolio
Table 27. Tiba Biotechnology Recent Developments
Table 28. Sangamo Therapeutics Company Information
Table 29. Sangamo Therapeutics Business Overview
Table 30. Sangamo Therapeutics RNA Vaccines Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
Table 31. Sangamo Therapeutics RNA Vaccines Product Portfolio
Table 32. Sangamo Therapeutics Recent Developments
Table 33. Moderna Therapeutics Company Information
Table 34. Moderna Therapeutics Business Overview
Table 35. Moderna Therapeutics RNA Vaccines Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
Table 36. Moderna Therapeutics RNA Vaccines Product Portfolio
Table 37. Moderna Therapeutics Recent Developments
Table 38. In-Cell-Art Company Information
Table 39. In-Cell-Art Business Overview
Table 40. In-Cell-Art RNA Vaccines Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
Table 41. In-Cell-Art RNA Vaccines Product Portfolio
Table 42. In-Cell-Art Recent Developments
Table 43. Ethris Company Information
Table 44. Ethris Business Overview
Table 45. Ethris RNA Vaccines Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
Table 46. Ethris RNA Vaccines Product Portfolio
Table 47. Ethris Recent Developments
Table 48. eTheRNA Company Information
Table 49. eTheRNA Business Overview
Table 50. eTheRNA RNA Vaccines Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
Table 51. eTheRNA RNA Vaccines Product Portfolio
Table 52. eTheRNA Recent Developments
Table 53. CureVac Company Information
Table 54. CureVac Business Overview
Table 55. CureVac RNA Vaccines Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
Table 56. CureVac RNA Vaccines Product Portfolio
Table 57. CureVac Recent Developments
Table 58. BioNTech Company Information
Table 59. BioNTech Business Overview
Table 60. BioNTech RNA Vaccines Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
Table 61. BioNTech RNA Vaccines Product Portfolio
Table 62. BioNTech Recent Developments
Table 63. Argos Therapeutics Company Information
Table 64. Argos Therapeutics Business Overview
Table 65. Argos Therapeutics RNA Vaccines Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
Table 66. Argos Therapeutics RNA Vaccines Product Portfolio
Table 67. Argos Therapeutics Recent Developments
Table 68. Global RNA Vaccines Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 69. Global RNA Vaccines Sales by Region (2020-2025) & (k units)
Table 70. Global RNA Vaccines Sales Market Share by Region (2020-2025)
Table 71. Global RNA Vaccines Sales by Region (2026-2031) & (k units)
Table 72. Global RNA Vaccines Sales Market Share by Region (2026-2031)
Table 73. Global RNA Vaccines Revenue by Region (2020-2025) & (US$ Million)
Table 74. Global RNA Vaccines Revenue Market Share by Region (2020-2025)
Table 75. Global RNA Vaccines Revenue by Region (2026-2031) & (US$ Million)
Table 76. Global RNA Vaccines Revenue Market Share by Region (2026-2031)
Table 77. North America RNA Vaccines Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 78. North America RNA Vaccines Sales by Country (2020-2025) & (k units)
Table 79. North America RNA Vaccines Sales by Country (2026-2031) & (k units)
Table 80. North America RNA Vaccines Revenue by Country (2020-2025) & (US$ Million)
Table 81. North America RNA Vaccines Revenue by Country (2026-2031) & (US$ Million)
Table 82. Europe RNA Vaccines Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 83. Europe RNA Vaccines Sales by Country (2020-2025) & (k units)
Table 84. Europe RNA Vaccines Sales by Country (2026-2031) & (k units)
Table 85. Europe RNA Vaccines Revenue by Country (2020-2025) & (US$ Million)
Table 86. Europe RNA Vaccines Revenue by Country (2026-2031) & (US$ Million)
Table 87. Asia Pacific RNA Vaccines Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 88. Asia Pacific RNA Vaccines Sales by Country (2020-2025) & (k units)
Table 89. Asia Pacific RNA Vaccines Sales by Country (2026-2031) & (k units)
Table 90. Asia Pacific RNA Vaccines Revenue by Country (2020-2025) & (US$ Million)
Table 91. Asia Pacific RNA Vaccines Revenue by Country (2026-2031) & (US$ Million)
Table 92. South America RNA Vaccines Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 93. South America RNA Vaccines Sales by Country (2020-2025) & (k units)
Table 94. South America RNA Vaccines Sales by Country (2026-2031) & (k units)
Table 95. South America RNA Vaccines Revenue by Country (2020-2025) & (US$ Million)
Table 96. South America RNA Vaccines Revenue by Country (2026-2031) & (US$ Million)
Table 97. Middle East and Africa RNA Vaccines Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 98. Middle East and Africa RNA Vaccines Sales by Country (2020-2025) & (k units)
Table 99. Middle East and Africa RNA Vaccines Sales by Country (2026-2031) & (k units)
Table 100. Middle East and Africa RNA Vaccines Revenue by Country (2020-2025) & (US$ Million)
Table 101. Middle East and Africa RNA Vaccines Revenue by Country (2026-2031) & (US$ Million)
Table 102. Global RNA Vaccines Sales by Type (2020-2025) & (k units)
Table 103. Global RNA Vaccines Sales by Type (2026-2031) & (k units)
Table 104. Global RNA Vaccines Sales Market Share by Type (2020-2025)
Table 105. Global RNA Vaccines Sales Market Share by Type (2026-2031)
Table 106. Global RNA Vaccines Revenue by Type (2020-2025) & (US$ Million)
Table 107. Global RNA Vaccines Revenue by Type (2026-2031) & (US$ Million)
Table 108. Global RNA Vaccines Revenue Market Share by Type (2020-2025)
Table 109. Global RNA Vaccines Revenue Market Share by Type (2026-2031)
Table 110. Global RNA Vaccines Price by Type (2020-2025) & (US$/unit)
Table 111. Global RNA Vaccines Price by Type (2026-2031) & (US$/unit)
Table 112. Global RNA Vaccines Sales by Application (2020-2025) & (k units)
Table 113. Global RNA Vaccines Sales by Application (2026-2031) & (k units)
Table 114. Global RNA Vaccines Sales Market Share by Application (2020-2025)
Table 115. Global RNA Vaccines Sales Market Share by Application (2026-2031)
Table 116. Global RNA Vaccines Revenue by Application (2020-2025) & (US$ Million)
Table 117. Global RNA Vaccines Revenue by Application (2026-2031) & (US$ Million)
Table 118. Global RNA Vaccines Revenue Market Share by Application (2020-2025)
Table 119. Global RNA Vaccines Revenue Market Share by Application (2026-2031)
Table 120. Global RNA Vaccines Price by Application (2020-2025) & (US$/unit)
Table 121. Global RNA Vaccines Price by Application (2026-2031) & (US$/unit)
Table 122. Key Raw Materials
Table 123. Raw Materials Key Suppliers
Table 124. RNA Vaccines Distributors List
Table 125. RNA Vaccines Customers List
Table 126. RNA Vaccines Industry Trends
Table 127. RNA Vaccines Industry Drivers
Table 128. RNA Vaccines Industry Restraints
Table 129. Authors List of This Report
List of Figures
Figure 1. Research Methodology
Figure 2. Research Process
Figure 3. Key Executives Interviewed
Figure 4. RNA Vaccines Product Image
Figure 5. Global RNA Vaccines Revenue (US$ Million), 2020 VS 2024 VS 2031
Figure 6. Global RNA Vaccines Market Size (2020-2031) & (US$ Million)
Figure 7. Global RNA Vaccines Sales (2020-2031) & (k units)
Figure 8. Global RNA Vaccines Average Price (US$/unit) & (2020-2031)
Figure 9. Individualized Cancer Treatment MRNA Vaccine Product Image
Figure 10. Infection Prevention MRNA Vaccine Product Image
Figure 11. Infectious Disease Treatment MRNA Vaccine Product Image
Figure 12. Infectious Disease Product Image
Figure 13. Cancer Product Image
Figure 14. Other Product Image
Figure 15. Global RNA Vaccines Revenue Share by Manufacturers in 2024
Figure 16. Global Manufacturers of RNA Vaccines, Manufacturing Sites & Headquarters
Figure 17. Global Top 5 and 10 RNA Vaccines Players Market Share by Revenue in 2024
Figure 18. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 19. Global RNA Vaccines Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Figure 20. Global RNA Vaccines Sales by Region in 2024
Figure 21. Global RNA Vaccines Revenue by Region in 2024
Figure 22. North America RNA Vaccines Market Size by Country in 2024
Figure 23. North America RNA Vaccines Sales Market Share by Country (2020-2031)
Figure 24. North America RNA Vaccines Revenue Market Share by Country (2020-2031)
Figure 25. United States RNA Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 26. Canada RNA Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 27. Europe RNA Vaccines Market Size by Country in 2024
Figure 28. Europe RNA Vaccines Sales Market Share by Country (2020-2031)
Figure 29. Europe RNA Vaccines Revenue Market Share by Country (2020-2031)
Figure 30. Germany RNA Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 31. France RNA Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 32. U.K. RNA Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 33. Italy RNA Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 34. Netherlands RNA Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 35. Asia Pacific RNA Vaccines Market Size by Country in 2024
Figure 36. Asia Pacific RNA Vaccines Sales Market Share by Country (2020-2031)
Figure 37. Asia Pacific RNA Vaccines Revenue Market Share by Country (2020-2031)
Figure 38. China RNA Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 39. Japan RNA Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 40. South Korea RNA Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 41. India RNA Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 42. Australia RNA Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 43. China Taiwan RNA Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 44. Southeast Asia RNA Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 45. Southeast Asia RNA Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 46. South America RNA Vaccines Market Size by Country in 2024
Figure 47. South America RNA Vaccines Sales Market Share by Country (2020-2031)
Figure 48. South America RNA Vaccines Revenue Market Share by Country (2020-2031)
Figure 49. Mexico RNA Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 50. Brazil RNA Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 51. Argentina RNA Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 52. Middle East and Africa RNA Vaccines Market Size by Country in 2024
Figure 53. Middle East and Africa RNA Vaccines Sales Market Share by Country (2020-2031)
Figure 54. Middle East and Africa RNA Vaccines Revenue Market Share by Country (2020-2031)
Figure 55. Turkey RNA Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 56. Saudi Arabia RNA Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 57. UAE RNA Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 58. Global RNA Vaccines Sales Market Share by Type (2020-2031)
Figure 59. Global RNA Vaccines Revenue Market Share by Type (2020-2031)
Figure 60. Global RNA Vaccines Price (US$/unit) by Type (2020-2031)
Figure 61. Global RNA Vaccines Sales Market Share by Application (2020-2031)
Figure 62. Global RNA Vaccines Revenue Market Share by Application (2020-2031)
Figure 63. Global RNA Vaccines Price (US$/unit) by Application (2020-2031)
Figure 64. RNA Vaccines Value Chain
Figure 65. RNA Vaccines Production Mode & Process
Figure 66. Direct Comparison with Distribution Share
Figure 67. Distributors Profiles
Figure 68. RNA Vaccines Industry Opportunities and Challenges
How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.